Currently an active site for therapeutic developments in Multi-system atrophy, Alzheimer's disease, Alzheimer's genetic risk, Autosomal dominant disease, Parkinson's disease. Current, active Phase 1-3 trials with AbbVie, Cortexyme, Eisai, Novartis, Roche, Genentech, Biohaven.